Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Aug;18(3):265-7.
doi: 10.1023/a:1006434008357.

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

J Vuky  1 , J McCaffrey, M Ginsberg, T Mariani, D F Bajorin, G J Bosl, R J Motzer
Affiliations
Clinical Trial

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

J Vuky et al. Invest New Drugs. 2000 Aug.

Abstract

Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. N Engl J Med. 1997 Jul 24;337(4):242-53 - PubMed
    1. J Clin Oncol. 1998 Jul;16(7):2500-4 - PubMed
    1. Cancer Invest. 1990;8(1):39-47 - PubMed
    1. J Clin Oncol. 1995 Aug;13(8):1975-84 - PubMed
    1. Cancer Res. 1987 Aug 15;47(16):4299-304 - PubMed

Publication types

LinkOut - more resources